Three TCRs previously cloned in our laboratory were selected for evaluation in these reporter cells: a TCR specific for a well characterized cytomegalovirus antigen (CMV) pp65 peptide (NLVPMVATV; HLA-A*02:01 restricted; [17]) and TCRs specific for peptides derived from the tumor antigens preferentially expressed antigen in melanoma (PRAME; SLLQHLIGL; HLA-A*02:01 restricted; [18]) and B cell-specific octamer binding protein-1 (BOB1; APAPTAVVL; HLA-B*07:02 restricted; [19]). The gene discussed is HLA-B; the disease is melanoma.